Pharmacokinetics of AGO178 in Participants With Liver Impairment

Inclusion Criteria: * Participants with liver disease confirmed within 3 months of screening. * If liver impairment is caused by alcohol use, participants must have abstained from alcohol use within 3 months of study start. * Participants must satisfy criteria for Child- Pugh Class A or B. Exclusion Criteria: * Use of other investigational drugs at the time of enrollment, or within 30 days or 5 half-lives of enrollment, whichever is longer. * Pregnant or nursing (lactating) women. * Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless using effective contraception during the study. * Donation or loss of 400 millilitres (mL) or more of blood within eight (8) weeks prior to initial dosing. * Significant illness within the two weeks prior to the dosing. * Participants with Child-Pugh alterations due to a non-liver disease (e.g. cancer or treatment related weight loss). Other protocol-defined inclusion/exclusion criteria may apply.